ORCA Therapeutics to Present at the 4th Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit

Amsterdam, The Netherlands – June 2025

AMSTERDAM, The Netherlands – Dr. Wenliang Dong, Ph.D., MBA, CEO of ORCA Therapeutics, will deliver a presentation at the 4th Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit, which will be held from June 4-5, 2025, in Munich, Germany. The presentation will focus on ORCA Therapeutics’ proprietary manufacturing processes and quality development strategies for ORCA-010, the company’s lead oncolytic adenovirus immunotherapy. Dr. Dong will share insights into the specialized manufacturing requirements and regulatory considerations for producing clinical-grade oncolytic viruses for cancer immunotherapy applications.

Dr. Wenliang Dong, Chief Executive Officer of ORCA Therapeutics and presenter at the summit, expressed his enthusiasm: “We are honored to participate in this important summit dedicated to advancing gene and cell therapy manufacturing. Our presentation will highlight the unique manufacturing challenges and solutions we have developed for ORCA-010, demonstrating how innovative production processes can support the successful clinical development of oncolytic immunotherapies. This platform provides an excellent opportunity to share our expertise and learn from other leaders in the field.”

The presentation will provide insights into ORCA’s approach to meeting CGTP safety and efficiency criteria, regulatory and GMP manufacturing standards, and optimizing vector production processes for oncolytic adenovirus therapies. The discussion will cover key aspects of quality control, scalability, and regulatory compliance that are essential for advancing oncolytic immunotherapies from clinical development to commercial manufacturing.

The summit is dedicated to accelerating progress in CMC and quality development of gene and cell therapy (GCT) products, bringing together industry leaders to explore new technologies, processes, digital solutions and automation that promise to revolutionize gene and cell therapies manufacturing.

ORCA Therapeutics is dedicated to advancing innovative cancer treatments and looks forward to engaging with the gene and cell therapy manufacturing community to discuss best practices and emerging solutions in this rapidly evolving field.

For more information about the summit, please visit the conference website.

About ORCA Therapeutics BV

ORCA Therapeutics BV is a leader in potent neo-adjuvant immuno-oncology therapeutics, specializing in oncolytic viruses and innovative gene therapy approaches. The company is dedicated to translating cutting-edge scientific discoveries into effective therapeutic solutions, addressing unmet medical needs and improving patient outcomes globally.

For more information about our mission and ongoing projects, visit www.orca-therapeutics.com

Media Contact

Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com